Who is sponsoring NCT04285814?

NCT04285814 is sponsored by Columbia University.

What drugs are being tested in NCT04285814?

Interventions in NCT04285814: Whole Fetal Cell (WFC) Testing.

What condition does NCT04285814 study?

NCT04285814 studies Copy Number Abnormality, Prenatal Diagnosis, Genetic Disease.

Is NCT04285814 still recruiting?

NCT04285814 is currently completed. Last updated 29 January 2025.

Last reviewed 2025-01-29 · How we verify

NCT04285814

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Technology Development for Noninvasive Prenatal Genetic Diagnosis Using Whole Fetal Cells From Maternal Peripheral Blood

Completed Last updated 29 January 2025

What this trial tests

trial testing Whole Fetal Cell (WFC) Testing in Copy Number Abnormality in 33 participants. Completed in 20 July 2023.

Timeline

1 September 2020

Primary endpoint
20 July 2023

20 July 2023

Quick facts

Lead sponsor	Columbia University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	33
Start date	1 September 2020
Primary completion	20 July 2023
Estimated completion	20 July 2023
Sites	2 locations across United States

Drugs / interventions tested

Whole Fetal Cell (WFC) Testing

Conditions studied

Copy Number Abnormality — all drugs for Copy Number Abnormality →
Prenatal Diagnosis — all drugs for Prenatal Diagnosis →
Genetic Disease — all drugs for Genetic Disease →

Sponsor

Columbia University

Who can join

18 and older, female only, with Copy Number Abnormality or Prenatal Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Amniocentesis (amnio) and chorionic villus sampling (CVS) can reliably detect many smaller DNA/genetic abnormalities that cannot be reliably diagnosed by cell-free noninvasive prenatal testing (NIPT) that is in widespread use. The investigators present evidence that a cell-based form of NIPT, here called Single Fetal Cell (SFC) testing, using a blood sample from the mother can detect most or all of the genetic abnormalities that are detected using amnio or CVS. This study proposes to compare the effectiveness of SFC testing in detecting abnormalities already detected by amnio or CVS in women already undergoing these tests as part of their clinical care because of fetal ultrasound abnormalities.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Columbia University trials

Trials by the same sponsor.

NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04285814 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Columbia University
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04285814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing